durvalumab monotherapy for patients with bcg-unresponsive carcinoma-in-situ bladder cancer
Published 2 years ago • 192 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
2:08
core1 trial: cg0070 plus pembrolizumab for bcg-unresponsive carcinoma-in-situ bladder cancer
-
0:27
cretostimogene plus pembrolizumab for bcg-unresponsive nmibc with cis #bladdercancer #cancer #news
-
1:00
trial of durvalumab for bladder cancer
-
0:49
current standards in bcg-unresponsive carcinoma in-situ and papillary nmibc
-
2:13
inspire: bladder-sparing chemort with durvalumab in ln urothelial cancer
-
1:40
safety results from phase 3b strong trial of durvalumab in patients with urinary tract carcinoma
-
4:38
danube trial: durvalumab alone or with tremelimumab for metastatic bladder cancer
-
6:08
immunotherapy approaches for nmibc
-
2:18
btcrc-gu15-023: duart plus adjuvant durvalumab in bladder cancer
-
3:31
the use of immunotherapy as a first-line therapy for bladder cancer
-
6:23
pembro monotherapy for participants with bcg–unresponsive hr nmibc shows anti-tumour activity
-
2:10
strong: fixed-dose durvalumab for utc
-
1:10
enhancing immunotherapy efficacy in bladder cancer
-
3:04
high-risk, bcg-unresponsive nmibc beyond rc: intravesical and systemic therapies
-
1:47
current and upcoming clinical trials in bladder cancer
-
1:21
how can we improve responses to immunotherapy in patients with bladder cancer?
-
2:03
tremelimumab and durvalumab therapy in lung cancer
-
2:03
durvalumab fda approval for bladder cancer
-
2:01
keynote-057 cohort b: pembrolizumab for bcg-unresponsive, high-risk nmibc